Serologic responses of 42 MERS-coronavirus-infected patients according to the disease severity

Jae Hoon Ko; Marcel A. Müller; Hyeri Seok; Ga Eun Park; Ji Yeon Lee; Sun Young Cho; Young Eun Ha; Jin Yang Baek; So Hyun Kim; Ji Man Kang; Yae Jean Kim; Ik Joon Jo; Chi Ryang Chung; Myong Joon Hahn; Christian Drosten; Cheol In Kang; Doo Ryeon Chung; Jae Hoon Song; Eun Suk Kang; Kyong Ran Peck

doi:10.1016/j.diagmicrobio.2017.07.006

Serologic responses of 42 MERS-coronavirus-infected patients according to the disease severity

Jae Hoon Ko, Marcel A. Müller, Hyeri Seok, Ga Eun Park, Ji Yeon Lee, Sun Young Cho, Young Eun Ha, Jin Yang Baek, So Hyun Kim, Ji Man Kang, Yae Jean Kim, Ik Joon Jo, Chi Ryang Chung, Myong Joon Hahn, Christian Drosten, Cheol In Kang, Doo Ryeon Chung, Jae Hoon Song, Eun Suk Kang, Kyong Ran Peck

Department of Internal Medicine

Research output: Contribution to journal › Article › peer-review

69 Scopus citations

Abstract

We evaluated serologic response of 42 Middle East respiratory syndrome coronavirus (MERS-CoV)-infected patients according to 4 severity groups: asymptomatic infection (Group 0), symptomatic infection without pneumonia (Group 1), pneumonia without respiratory failure (Group 2), and pneumonia progressing to respiratory failure (Group 3). None of the Group 0 patients showed seroconversion, while the seroconversion rate gradually increased with increasing disease severity (0.0%, 60.0%, 93.8%, and 100% in Group 0, 1, 2, 3, respectively; P = 0.001). Group 3 patients showed delayed increment of antibody titers during the fourth week, while Group 2 patients showed robust increment of antibody titer during the third week. Among patients having pneumonia, 75% of deceased patients did not show seroconversion by the third week, while 100% of the survived patients were seroconverted (P = 0.003).

Original language	English
Pages (from-to)	106-111
Number of pages	6
Journal	Diagnostic Microbiology and Infectious Disease
Volume	89
Issue number	2
DOIs	https://doi.org/10.1016/j.diagmicrobio.2017.07.006
State	Published - Oct 2017

Keywords

Antibody
Middle East respiratory syndrome coronavirus
Prognosis
Serologic response

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.diagmicrobio.2017.07.006

Cite this

Ko, J. H., Müller, M. A., Seok, H., Park, G. E., Lee, J. Y., Cho, S. Y., Ha, Y. E., Baek, J. Y., Kim, S. H., Kang, J. M., Kim, Y. J., Jo, I. J., Chung, C. R., Hahn, M. J., Drosten, C., Kang, C. I., Chung, D. R., Song, J. H., Kang, E. S., & Peck, K. R. (2017). Serologic responses of 42 MERS-coronavirus-infected patients according to the disease severity. Diagnostic Microbiology and Infectious Disease, 89(2), 106-111. https://doi.org/10.1016/j.diagmicrobio.2017.07.006

@article{87842a73457a440ca97b884ae8d20061,

title = "Serologic responses of 42 MERS-coronavirus-infected patients according to the disease severity",

abstract = "We evaluated serologic response of 42 Middle East respiratory syndrome coronavirus (MERS-CoV)-infected patients according to 4 severity groups: asymptomatic infection (Group 0), symptomatic infection without pneumonia (Group 1), pneumonia without respiratory failure (Group 2), and pneumonia progressing to respiratory failure (Group 3). None of the Group 0 patients showed seroconversion, while the seroconversion rate gradually increased with increasing disease severity (0.0\%, 60.0\%, 93.8\%, and 100\% in Group 0, 1, 2, 3, respectively; P = 0.001). Group 3 patients showed delayed increment of antibody titers during the fourth week, while Group 2 patients showed robust increment of antibody titer during the third week. Among patients having pneumonia, 75\% of deceased patients did not show seroconversion by the third week, while 100\% of the survived patients were seroconverted (P = 0.003).",

keywords = "Antibody, Middle East respiratory syndrome coronavirus, Prognosis, Serologic response",

author = "Ko, \{Jae Hoon\} and M{\"u}ller, \{Marcel A.\} and Hyeri Seok and Park, \{Ga Eun\} and Lee, \{Ji Yeon\} and Cho, \{Sun Young\} and Ha, \{Young Eun\} and Baek, \{Jin Yang\} and Kim, \{So Hyun\} and Kang, \{Ji Man\} and Kim, \{Yae Jean\} and Jo, \{Ik Joon\} and Chung, \{Chi Ryang\} and Hahn, \{Myong Joon\} and Christian Drosten and Kang, \{Cheol In\} and Chung, \{Doo Ryeon\} and Song, \{Jae Hoon\} and Kang, \{Eun Suk\} and Peck, \{Kyong Ran\}",

note = "Publisher Copyright: {\textcopyright} 2017 Elsevier Inc.",

year = "2017",

month = oct,

doi = "10.1016/j.diagmicrobio.2017.07.006",

language = "English",

volume = "89",

pages = "106--111",

journal = "Diagnostic Microbiology and Infectious Disease",

issn = "0732-8893",

publisher = "Elsevier Inc.",

number = "2",

}

Ko, JH, Müller, MA, Seok, H, Park, GE, Lee, JY, Cho, SY, Ha, YE, Baek, JY, Kim, SH, Kang, JM, Kim, YJ , Jo, IJ , Chung, CR, Hahn, MJ, Drosten, C, Kang, CI , Chung, DR, Song, JH, Kang, ES & Peck, KR 2017, 'Serologic responses of 42 MERS-coronavirus-infected patients according to the disease severity', Diagnostic Microbiology and Infectious Disease, vol. 89, no. 2, pp. 106-111. https://doi.org/10.1016/j.diagmicrobio.2017.07.006

TY - JOUR

T1 - Serologic responses of 42 MERS-coronavirus-infected patients according to the disease severity

AU - Ko, Jae Hoon

AU - Müller, Marcel A.

AU - Seok, Hyeri

AU - Park, Ga Eun

AU - Lee, Ji Yeon

AU - Cho, Sun Young

AU - Ha, Young Eun

AU - Baek, Jin Yang

AU - Kim, So Hyun

AU - Kang, Ji Man

AU - Kim, Yae Jean

AU - Jo, Ik Joon

AU - Chung, Chi Ryang

AU - Hahn, Myong Joon

AU - Drosten, Christian

AU - Kang, Cheol In

AU - Chung, Doo Ryeon

AU - Song, Jae Hoon

AU - Kang, Eun Suk

AU - Peck, Kyong Ran

PY - 2017/10

Y1 - 2017/10

N2 - We evaluated serologic response of 42 Middle East respiratory syndrome coronavirus (MERS-CoV)-infected patients according to 4 severity groups: asymptomatic infection (Group 0), symptomatic infection without pneumonia (Group 1), pneumonia without respiratory failure (Group 2), and pneumonia progressing to respiratory failure (Group 3). None of the Group 0 patients showed seroconversion, while the seroconversion rate gradually increased with increasing disease severity (0.0%, 60.0%, 93.8%, and 100% in Group 0, 1, 2, 3, respectively; P = 0.001). Group 3 patients showed delayed increment of antibody titers during the fourth week, while Group 2 patients showed robust increment of antibody titer during the third week. Among patients having pneumonia, 75% of deceased patients did not show seroconversion by the third week, while 100% of the survived patients were seroconverted (P = 0.003).

AB - We evaluated serologic response of 42 Middle East respiratory syndrome coronavirus (MERS-CoV)-infected patients according to 4 severity groups: asymptomatic infection (Group 0), symptomatic infection without pneumonia (Group 1), pneumonia without respiratory failure (Group 2), and pneumonia progressing to respiratory failure (Group 3). None of the Group 0 patients showed seroconversion, while the seroconversion rate gradually increased with increasing disease severity (0.0%, 60.0%, 93.8%, and 100% in Group 0, 1, 2, 3, respectively; P = 0.001). Group 3 patients showed delayed increment of antibody titers during the fourth week, while Group 2 patients showed robust increment of antibody titer during the third week. Among patients having pneumonia, 75% of deceased patients did not show seroconversion by the third week, while 100% of the survived patients were seroconverted (P = 0.003).

KW - Antibody

KW - Middle East respiratory syndrome coronavirus

KW - Prognosis

KW - Serologic response

UR - https://www.scopus.com/pages/publications/85027411812

U2 - 10.1016/j.diagmicrobio.2017.07.006

DO - 10.1016/j.diagmicrobio.2017.07.006

M3 - Article

C2 - 28821364

AN - SCOPUS:85027411812

SN - 0732-8893

VL - 89

SP - 106

EP - 111

JO - Diagnostic Microbiology and Infectious Disease

JF - Diagnostic Microbiology and Infectious Disease

IS - 2

ER -

Serologic responses of 42 MERS-coronavirus-infected patients according to the disease severity

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this